Key TakeawaysIllumina said it would take a $1.47 billion goodwill impairment charge related to its spinoff of cancer testing company GRAIL.Illumina also said it would take a $420 million charge for GRAIL's in-process R&D.Illumina's purchase of GRAIL prior to regulatory approval had been steeped in controversy for years. The breakup with GRAIL (GRAL) was costly for Illumina (ILMN). The gene sequencing company wrote in a regulatory filing Thursday that it would take a $1.47 billion goodwill impairment charge ...